{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-003575","form_type":"8-K","ticker":"NRC","cik":"0000070487","company_name":"NRC HEALTH","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.811486+00:00","generated_at":"2026-06-19T09:53:26.909167+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NRC Health reports Q4 EPS $0.27, down from $0.38; FY revenue +7% but EPS $1.27 vs $1.46","bullets":["Q4 diluted EPS $0.27 (vs $0.38 in Q4 2021); full-year 2022 diluted EPS $1.27 (vs $1.46).","FY 2022 revenue grew 7% year-over-year driven by core Human Understanding Program; Canadian ops phase-out partially offset.","$2.6M reclassification from substantial liquidation of Canadian subsidiary impacted other expense.","Capital allocation: $21.0M dividends, $27.6M share repurchases, $12.2M innovation/growth in 2022.","New client wins including St. Bernards Healthcare; received Best in KLAS 2023 Award for Patient Experience Improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-003575","json":"https://secwatch.observer/filing/0001437749-23-003575.json","markdown":"https://secwatch.observer/filing/0001437749-23-003575.md","text":"https://secwatch.observer/filing/0001437749-23-003575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/70487/000143774923003575/0001437749-23-003575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/70487/000143774923003575/nrc20230215_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:53:26.909167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c810a843105acb356b271e0e355ba4a14577fe4","claim":"NRC HEALTH reported financial results for fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On February 14, 2023, National Research Corporation, a Delaware corporation (the \"Company\"), issued a press release announcing its financial and operating results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/70487/000143774923003575/0001437749-23-003575-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}